masoprocol
Trade name: actinex
Approved
Sep 4, 1992
Misoprostol is an antineoplastic drug used to treat skin growths caused by sun exposure. Masoprocol is a novel antineoplastic agent was used for the treatment of actinic keratoses (precancerous skin growths that can become malignant if left untreated). Masoprocol was withdrawn from the U.S. market in June 1996. It is not known exactly how Masoprocol works. Studies have shown that masoprocol is a potent 5-lipoxygenase inhibitor and has antiproliferative activity against keratinocytes in tissue culture, but the relationship between this activity and its effectiveness in actinic keratoses is unknown. Masoprocol also inhibits prostaglandins but the significance of this action is not yet known. Symptoms of overdose or allergic reaction include bluish coloration of skin, dizziness, severe, or feeling faint, wheezing or trouble in breathing. — NCATS
Clinical trial activity
2 trials · 3 clinical orgs · 1 marketing orgs
Earliest trial started Jun 1, 2005 (NCT00313534)
Timeline
1990s
- Sep 4, 1992
University of Arizona — Earliest FDA Approval
- Sep 4, 1992
University of Arizona — NDA Organization
- Sep 4, 1992
University of Arizona — NDA Secondary Org
Indications
Approved for
Studied for
Mechanism of action
IGF1R inhibitor
ERBB2 inhibitor
- Unspecified targetOTHER
Unknown
Approval history
- approvedSep 4, 1992
Chemistry & pharmacology
SMILES
C[C@H](Cc1ccc(O)c(O)c1)[C@@H](C)Cc1ccc(O)c(O)c1- Mol. weight
- 302.37 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Discontinued
Oral
No
Parenteral
No
Topical
Yes
Sources
- ChEMBLCHEMBL313972 ↗
- WikipediaMasoprocol ↗
- NCATS7BO8G1BYQU ↗
- ChEMBLCHEMBL52 ↗
- ChEMBLCHEMBL3545025 ↗
Also known as
- actinex
- actinex
- actinex
- actinex
- chx-100
- chx-100
- erythro-nordihydroguaiaretic acid
- erythro-nordihydroguaiaretic acid
- insm-18
- insm-18
- masoprocol
- masoprocol
- masoprocol
- masoprocol
- masoprocol
- masoprocol
- masoprocol
- masoprocol
- masoprocol
- masoprocol
- masoprocolum
- masoprocolum
- meso-1,4-bis(3,4-dihydroxyphenyl)-2,3-dimethylbutane
- meso-1,4-bis(3,4-dihydroxyphenyl)-2,3-dimethylbutane
- meso-2,3-bis(3,4-dihydroxyphenylmethyl)butane
- meso-2,3-bis(3,4-dihydroxyphenylmethyl)butane
- meso-4,4'-(2,3-dimethyl-1,4-butanediyl)bis(pyrocatechol)
- meso-4,4'-(2,3-dimethyl-1,4-butanediyl)bis(pyrocatechol)
- meso-4,4'-(2,3-dimethyltetramethylene)dipyrocatechol
- meso-4,4'-(2,3-dimethyltetramethylene)dipyrocatechol
- meso-4-[4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol
- meso-4-[4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol
- meso-ndga
- meso-ndga
- meso-ndga
- meso-nordihydroguaiaretic acid
- meso-nordihydroguaiaretic acid
- meso-nordihydroguaiaretic acid
- mesonordihydroguaiaretic acid
- meso-β,γ-dimethyl-α,δ-bis(3,4-dihydroxyphenyl)butan
- meso-β,γ-dimethyl-α,δ-bis(3,4-dihydroxyphenyl)butan
- nordihydroguaiaretic acid
- nordihydroguaiaretic acid
- nordihydroguaiaretic acid
- nordihydroguaiaretic acid
- nordihydroguaiaretic acid
- nordihydroguaiaretic acid
- nordihydroguaiaretic acid
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00678015 | Phase 2 | May 1, 2008 | Insmed, Inc., University of California, San Francisco |
| NCT00313534 | Phase 1 | Jun 1, 2005 | National Cancer Institute (NCI), University of California, San Francisco |
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of California, San Francisco | Academic/Hospital | 2 | 2 | 2 | 2005 |
| Insmed, Inc. | For profit | 1 | 0 | 1 | 2008 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2005 |
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| University of Arizona | Academic/Hospital | NDA | Sep 4, 1992 |
| University of Arizona | Academic/Hospital | NDA2 | Sep 4, 1992 |